Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure
about
Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patientsClinical perspectives on echinocandin resistance among Candida speciesEchinocandin resistance: an emerging clinical problem?Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancerRole of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.Drug-resistant Candida glabrata infection in cancer patients.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Abdominal candidiasis is a hidden reservoir of echinocandin resistance.Management of invasive candidiasis in nonneutropenic ICU patients.Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream InfectionDose escalation studies with caspofungin against Candida glabrata.Cost-Effectiveness Analysis of Multiplex PCR with Magnetic Resonance Detection versus Empiric or Blood Culture-Directed Therapy for Management of Suspected Candidemia.Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.Heteroresistance to Fluconazole Is a Continuously Distributed Phenotype among Candida glabrata Clinical Strains Associated with In Vivo Persistence.Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion MethodOur 2014 approach to breakthrough invasive fungal infections.Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality.Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis.Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia.Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis.Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria.Echinocandin Resistance in Candida Species: a Review of Recent Developments.Pan-azole-resistant Candida tropicalis carrying homozygous erg11 mutations at position K143R: a new emerging superbug?The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints.[Strategies for antifungal treatment failure in intensive care units].Next-generation sequencing offers new insights into the resistance of Candida spp. to echinocandins and azoles.Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients.In vitro activity of 23 tea extractions and epigallocatechin gallate against Candida species.Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.Candida glabrata candidemia.Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.
P2860
Q26852351-2078FEC8-4C85-460C-8390-7CFBF593E8C2Q28082538-81B4245A-835A-4B1C-834B-AB582B1EF1B3Q28544739-3D6F1891-B49F-4EA6-97C1-353AF575B784Q33622743-D95FE45C-A5BF-4E73-8AFB-8794A2A8548EQ33712955-E8AA2F21-7988-4CE6-8F8D-17180DD785F0Q33798097-26025E01-F6B8-4CCB-9B16-E7F7627ACF49Q34058099-1332DE17-A081-45B4-A747-FC60A926D253Q34426755-46173C29-FA3C-4D58-8E35-630147ABC6B3Q34505582-8F790607-0F41-459D-BAA3-C20934154AA4Q34597421-336622CB-9ED2-4277-9E5B-54984A6C59D2Q35122093-0F92FBAF-8C0D-44A7-B3C0-0DF9A8A26614Q35775400-40C79ADA-0C32-4811-B888-9EB94DF1A2F0Q36158263-4875CEC2-3791-408D-87CF-162B895D14CEQ36158489-BDF216A1-CCA9-40C8-8F38-0AB2225073D0Q36290758-E7D8C4AC-6BBB-4A78-AC1C-26D98FD9FB9EQ36376559-CF1B1608-7B84-40F1-8063-9AC65C3264CEQ36620896-376DB966-BDFD-4FEC-B90F-650978960014Q37124005-1351D3C1-1E63-4EC8-9A20-1BF75E19B8C0Q37168667-DC103D19-A03D-41E3-8A27-08D73369962BQ37335848-7646C0D3-C3D5-4064-B01C-F70EE70CFB1AQ37538775-05AD4898-F88B-4750-AEFB-154BD1AB9CF1Q38223105-A51A5B77-93F1-4BBF-90E1-B9210CC67061Q38236893-D92FBA2E-CA86-49FA-9F19-F9E8C66A7F6CQ38412398-515AE42C-EAA1-4F55-B475-8EA7FB80BABDQ38531765-4887AB6A-F4C4-4ECB-ABB4-440D81D67162Q38535647-8C3B62A7-E829-473C-8CED-48A1C3F7421CQ38589279-B83059A5-5323-48CD-A353-4A782B35F7A7Q38916677-EC6B4377-E484-47F8-B0B1-4AA049BC10D8Q38988521-2D4E0535-AA13-41BE-97AC-DC16DD2023AEQ39033115-BC860004-08EE-483E-89E3-BCB05F9C4FC0Q40045635-5E42683C-73D6-4F90-B80D-C880F52DD475Q40202924-97BB6F4D-4819-4210-B883-74661714A52FQ40542769-319DEB6B-C56A-42AB-A4CF-CED814CB46E7Q41010354-90B24D51-0A62-46AF-B656-716AE6F9738FQ41199783-EA6F5E93-3D98-40BB-8173-C2AF0A4AF4BCQ41204913-261ED700-3CC1-44C4-872B-AD05F6FA7729Q41531264-4D9A874A-E40B-4350-BFC2-918528FAEEFCQ41908678-8AB0FF95-144D-4977-A62C-DC1F601E92D2Q42061335-602BC4FA-363D-4AF7-A8D4-2B721863AC56Q43125888-633BD471-845C-4FA7-A5BE-C77BE5D3AE59
P2860
Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Caspofungin MICs correlate wit ...... nd prior echinocandin exposure
@en
Caspofungin MICs correlate wit ...... d prior echinocandin exposure.
@nl
type
label
Caspofungin MICs correlate wit ...... nd prior echinocandin exposure
@en
Caspofungin MICs correlate wit ...... d prior echinocandin exposure.
@nl
prefLabel
Caspofungin MICs correlate wit ...... nd prior echinocandin exposure
@en
Caspofungin MICs correlate wit ...... d prior echinocandin exposure.
@nl
P2093
P2860
P356
P1476
Caspofungin MICs correlate wit ...... nd prior echinocandin exposure
@en
P2093
Cassaundra L Updike
Cornelius J Clancy
Ellen G Press
M Hong Nguyen
Ryan K Shields
P2860
P304
P356
10.1128/AAC.00136-13
P407
P577
2013-05-13T00:00:00Z